-
Material Transfer Agreement (MTA)
http://web.research.colostate.edu/(X(1)S(tmu43k55tvrsiz55ogbggnzx))/OSP/mta.aspx?AspxAutoDetectCookieSupport=1[2012/07/13
16:30:55]
Office Links
Finding Information:
Internal Resources:
Home
Contact Information
Organization Chart
Staff Directory
Policies and Manuals
Export Control
Material Transfer Agreement (MTA)
Funding Opportunities
Proposal Preparation Resources
Accounting Resources
Research Data Center
Internal Research Contacts
External Research Contacts
Research Site Map
CSU A-Z
Search CSU
Directories
Research Portal (restricted)
Check Email (restricted)
Material Transfer Agreement (MTA)
Scientific materials being transferred between CSU and another
organization must be formally coveredwith a Material Transfer
Agreement (MTA). The purpose of the MTA is to protect the
intellectual andother property rights of the provider while
permitting research with the material to proceed. Theseagreements
describe the terms and purpose of the exchange, including
intellectual property rights,liability issues, publication,
confidentiality, royalties or other financial terms, and the
specifics of thematerials and their transfer.
General Information (PDF)Instructions UBMTA (PDF)Instructions
Non UBMTA (PDF)
Forms
The Uniform Biological Material Transfer Agreement (PDF)UBMTA
Implementing Letter (Fillable PDF)CSU Biological MTA Long Form
(Fillable PDF)CSU Biological MTA Short Form (Fillable PDF)Material
Transfer Agreement (Fillable PDF)
Other Resources
UBMTA Members
Material Transfer in Academia an informative booklet from COGR
about entering into MaterialTransfer Agreements. (PDF)
For additional information, please contact:
Betty [email protected](970) 491-1554
Contact CSU | Disclaimer | Equal Opportunity | Privacy
Statement
Colorado State University, Fort Collins, CO 80523 USA 2007
Colorado State University
This page has been accessed 5312 times.
http://web.research.colostate.edu/OSP/default.aspxhttp://web.research.colostate.edu/OSP/default.aspxhttp://web.research.colostate.edu/OSP/contact.aspxhttp://web.research.colostate.edu/OSP/contact.aspxhttp://web.research.colostate.edu/OSP/staff_chart.aspxhttp://web.research.colostate.edu/OSP/staff_chart.aspxhttp://web.research.colostate.edu/OSP/policies.aspxhttp://web.research.colostate.edu/OSP/policies.aspxhttp://web.research.colostate.edu/OSP/export.aspxhttp://web.research.colostate.edu/OSP/export.aspxhttp://web.research.colostate.edu/OSP/mta.aspxhttp://web.research.colostate.edu/OSP/mta.aspxhttp://web.research.colostate.edu/OSP/funding.aspxhttp://web.research.colostate.edu/OSP/funding.aspxhttp://web.research.colostate.edu/OSP/proposal.aspxhttp://web.research.colostate.edu/OSP/proposal.aspxhttp://web.research.colostate.edu/OSP/accounting.aspxhttp://web.research.colostate.edu/OSP/accounting.aspxhttp://web.research.colostate.edu/datacenter/http://web.research.colostate.edu/datacenter/http://web.research.colostate.edu/OSP/internal.aspxhttp://web.research.colostate.edu/OSP/internal.aspxhttp://web.research.colostate.edu/OSP/external.aspxhttp://web.research.colostate.edu/OSP/external.aspxhttp://web.research.colostate.edu/vpr/sitemap.aspxhttp://web.research.colostate.edu/vpr/sitemap.aspxhttp://search.colostate.edu/search-atoz.aspxhttp://search.colostate.edu/search-atoz.aspxhttp://search.colostate.edu/search-csu.aspxhttp://search.colostate.edu/search-csu.aspxhttp://search.colostate.edu/search-directory.aspxhttp://search.colostate.edu/search-directory.aspxhttp://padroni.is.colostate.edu:7778/portal/page/portal/CSUCAP/Researchhttp://padroni.is.colostate.edu:7778/portal/page/portal/CSUCAP/Researchhttp://mail.colostate.edu/http://mail.colostate.edu/mailto:[email protected]://search.colostate.edu/index.asp?url=contact_informationhttp://welcome.colostate.edu/info-disclaimer.aspxhttp://welcome.colostate.edu/info-equalop.aspxhttp://welcome.colostate.edu/info-privacy.aspxhttp://web.research.colostate.edu/OSPhttp://www.colostate.edu/http://vpr.colostate.edu/
-
Revised 12/14/07 sf
Material Transfer Agreements
General Information
Scientific materials being transferred between CSU and another
organization must be formally
covered with a Material Transfer Agreement (MTA). The purpose of
the MTA is to protect the
intellectual and other property rights of the provider while
permitting research with the material
to proceed. These agreements describe the terms and purpose of
the exchange, including
intellectual property rights, liability issues, publication,
confidentiality, royalties or other
financial terms, and the specifics of the materials and their
transfer. The MTAs may be between
CSU and other universities, governmental agencies such as NIH,
or, more frequently,
commercial entities. It is important to recognize that these
agreements are between institutions,
not individuals. Sponsored Programs is responsible for review
and approval of all MTAs for
materials coming into CSU and for non-UBMTA outgoing
materials.
IMPORTANT
Private companies generally regard any materials they provide to
the academic community as
highly proprietary and provide the materials as a favor only if
the recipient organization agrees to
certain terms. Usually the terms involve some first right of the
provider to a license to any
discoveries made by the Principal Investigator (PI) as a result
of using the companys materials.
Some of the company-proposed terms may be in conflict with CSUs
policies and/or federal
guidelines. The staff in Sponsored Programs will work with the
provider company to arrive at
terms which are consistent with CSU policy and, for NIH
Guidelines if the PI is a NIH grant
recipient. Deviations from CSU policy will require the approval
of the VPRs Office.
If the material is the subject of a patent application which has
been filed by CSU, OR the
material incorporates any substance which was received from a
third party under an MTA, you
should consult your Senior Research Administrator for
assistance.
NIH Guidelines:
The National Institutes of Health (NIH) published its policy
statement in the December 23, 1999
Federal Register entitled "Principles and Guidelines for
Recipients of NIH Research Grants and
Contracts on Obtaining and Disseminating Biomedical Research
Resources". These guidelines
are intended to help federal grant recipients determine
reasonable terms and conditions for
making NIH funded research resources available to others and
under what terms and conditions
NIH funded scientist should receive materials from others. The
Guidelines can be found at
http://ott.od.nih.gov/policy/rt_guide.html.
For all MTA transactions please complete the MTA Information
Sheet; this form can be found at
(http://web.research.colostate.edu/osp/mta/pdf/newmta.pdf. The
format of the agreement to be
used for material transfers will depend upon whether or not the
other party is a member to the
Universal Biomedical Material Transfer Agreement (UBMTA). If the
other party is a participant
in the UBMTA, the following procedures apply. If they are not a
member to the UBMTA,
please refer to the section labeled NON-UBMTA Members.
-
Updated 12/14/2007 sf
Material Transfer Agreements
Instructions - UBMTA For all MTA transactions please complete
the MTA Information Sheet; this form can be found at
(http://web.research.colostate.edu/osp/mta/pdf/newmta.pdf.
Background: On March 8, 1995, the National Institutes of Health
(NIH) (on behalf of the Public Health Service and the Centers for
Disease Control) published the final version of the Uniform
Biological Material Transfer Agreement (UBMTA) and a Simple Letter
Agreement for the Transfer of Non-Proprietary Biological Material.
For institutions, such as CSU, which have signed the UBMTA Master
Agreement, materials can be transferred under the terms of the
UBMTA upon execution of an Implementing Letter for the particular
transfer. The UBMTA is appropriate for most transfers of materials
between CSU and other academic institutions. To determine if the
academic institution you are working with is a signatory to the
UBMTA, click on this link
http://www.autm.net/Technology_Transfer_Resources/8199.htm.
Process: Out-Going Materials The Scientist from the Recipient
organization should complete three copies of the Implementing
Letter and obtain signatures as necessary from his/her
organization. Upon receipt of the signed copies, CSUs PI should
sign the Implementing Letters where indicated and return one fully
executed copy along with the materials to the Recipient. The second
copy of the Letter should be retained by the CSU PI with the third
copy being sent to Sponsored Programs. In-Coming Materials CSUs PI
should obtain and sign three copies of the Implementing Letter as
the Recipient. The copies along with the MTA Information Sheet
should be forwarded to the Senior Research Administrator assigned
to their College for review and approval. The Letters will be
returned to the PI to be mailed to the Provider with a request to
return two fully signed copies. One copy should be retained by the
CSU PI and the second forwarded to Sponsored Programs. If the
incoming material is subject to approval of the Research Integrity
and Compliance Review Office, this approval must be obtained prior
to executing the MTA. If you have questions about MTAs, contact the
SRA responsible for your college.
-
Updated 12/17/07 sf
Material Transfer Agreements Non UBMTA Members
Instructions Non UBMTA
For all MTA transactions please complete the MTA Information
Sheet; this form can be found at
(http://web.research.colostate.edu/osp/mta/pdf/newmta.pdf.
Out-Going Materials - For materials being transferred from CSU,
a model MTA form can be
found at
http://web.research.colostate.edu/osp/mta/pdf/csumta.pdf. Please
provide the Recipient
with this link. The Recipient should complete and sign three
separate copies of this agreement
and forward them to the PI. When the copies are received, the PI
should sign as the Provider
Scientist and forward the copies to Sponsored Programs (SP). SP
will review and approve the
documents and return two copies to the PI; one for your files
and one to be sent to the Recipient
with the materials.
In-Coming Materials - For materials being transferred to CSU,
the other party typically uses its
own MTA form, yet your handling of the MTA in the following way
will expedite the process.
Review the MTA carefully for terms that could cause your
laboratory difficulty. These might
include confidentiality issues, publication issues, quantities
or timing of materials transferred.
Watch out for terms that would be in conflict with other terms
(research contract, other MTAs, or
government sponsor requirements) and discuss with your Senior
Research Administrator (SRA)
(http://web.research.colostate.edu/OSP/staff_detail.aspx).
If the incoming material is subject to approval of the
Regulatory Compliance Office, this approval must be obtained prior
to the execution of the MTA.
Sign and date it as the technical (not institutional)
representative this may require adding a signature block.
Send three originals of the agreement and one copy of the MTA
Information Sheet to the SRA responsible for your college, 408 USC,
2002 Campus Delivery.
At Sponsored Programs the MTA will be checked for intellectual
property rights, liability issues, and other legal matters.
If the terms are inconsistent with University policy, the SRA
will attempt to negotiate acceptable language with the other party,
keeping you informed.
If the terms are acceptable, the SRA will obtain an authorized
signature, and the MTA will be returned to you for delivery to the
other party.
Be sure to retain a copy of the MTA, since you, as the
Recipient, will be obligated to abide by its terms. If any of the
terms are unclear, contact the SRA for your college.
Please allow plenty of time for an MTA to be processed since it
can take several days to negotiate mutually acceptable terms.
If you have questions about MTAs, contact the SRA responsible
for your college.
-
Updated 12/17/07 sf
The Uniform Biological Material Transfer Agreement
March 8, 1995
I. Definitions:
1. PROVIDER: Organization providing the ORIGINAL MATERIAL. The
name and
address of this party will be specified in an implementing
letter.
2. PROVIDER SCIENTIST: The name and address of this party will
be specified in an
implementing letter.
3. RECIPIENT: Organization receiving the ORIGINAL MATERIAL. The
name and
address of this party will be specified in an implementing
letter.
4. RECIPIENT SCIENTIST: The name and address of this party will
be specified in an
implementing letter.
5. ORIGINAL MATERIAL: The description of the material being
transferred will be
specified in an implementing letter.
6. MATERIAL: ORIGINAL MATERIAL, PROGENY, and UNMODIFIED
DERIVATIVES. The MATERIAL shall not include: (a) MODIFICATIONS,
or (b) other
substances created by the RECIPIENT through the use of the
MATERIAL which are not
MODIFICATIONS, PROGENY, or UNMODIFIED DERIVATIVES.
7. PROGENY: Unmodified descendant from the MATERIAL, such as
virus from virus,
cell from cell, or organism from organism.
8. UNMODIFIED DERIVATIVES: Substances created by the RECIPIENT
which
constitute an unmodified functional subunit or product expressed
by the ORIGINAL
MATERIAL. Some examples include: subclones of unmodified cell
lines, purified or
fractionated subsets of the ORIGINAL MATERIAL, proteins
expressed by DNA/RNA supplied
by the PROVIDER, or monoclonal antibodies secreted by a
hybridoma cell line.
9. MODIFICATIONS: Substances created by the RECIPIENT which
contain/incorporate the MATERIAL.
10. COMMERCIAL PURPOSES: The sale, lease, license, or other
transfer of the
MATERIAL or MODIFICATIONS to a for-profit organization.
COMMERCIAL PURPOSES
shall also include uses of the MATERIAL or MODIFICATIONS by any
organization, including
RECIPIENT, to perform contract research, to screen compound
libraries, to produce or
manufacture products for general sale, or to conduct research
activities that result in any sale,
lease, license, or transfer of the MATERIAL or MODIFICATIONS to
a for-profit organization.
However, industrially sponsored academic research shall not be
considered a use of the
-
Updated 12/17/07 sf
MATERIAL or MODIFICATIONS for COMMERCIAL PURPOSES per se, unless
any of the
above conditions of this definition are met.
11. NONPROFIT ORGANIZATION(S): A university or other institution
of higher
education or an organization of the type described in section
501(c)(3) of the Internal Revenue
Code of 1954 (26 U.S.C. 501(c)) and exempt from taxation under
section 501(a) of the Internal
Revenue Code (26 U.S.C. 501(a)) or any nonprofit scientific or
educational organization
qualified under a state nonprofit organization statute. As used
herein, the term also includes
government agencies.
II. Terms and Conditions of this Agreement:
1. The PROVIDER retains ownership of the MATERIAL, including any
MATERIAL
contained or incorporated in MODIFICATIONS.
2. The RECIPIENT retains ownership of: (a) MODIFICATIONS (except
that, the
PROVIDER retains ownership rights to the MATERIAL included
therein), and (b) those
substances created through the use of the MATERIAL or
MODIFICATIONS, but which are not
PROGENY, UNMODIFIED DERIVATIVES or MODIFICATIONS (i.e., do not
contain the
ORIGINAL MATERIAL, PROGENY, UNMODIFIED DERIVATIVES). If either 2
(a) or 2 (b)
results from the collaborative efforts of the PROVIDER and the
RECIPIENT, joint ownership
may be negotiated.
3. The RECIPIENT and the RECIPIENT SCIENTIST agree that the
MATERIAL:
(a) is to be used solely for teaching and academic research
purposes;
(b) will not be used in human subjects, in clinical trials, or
for diagnostic
purposes involving human subjects without the written consent of
the
PROVIDER;
(c) is to be used only at the RECIPIENT organization and only in
the
RECIPIENT SCIENTIST's laboratory under the direction of the
RECIPIENT
SCIENTIST or others working under his/her direct supervision;
and
(d) will not be transferred to anyone else within the RECIPIENT
organization
without the prior written consent of the PROVIDER.
4. The RECIPIENT and the RECIPIENT SCIENTIST agree to refer to
the PROVIDER
any request for the MATERIAL from anyone other than those
persons working under the [[Page
12774]] RECIPIENT SCIENTIST's direct supervision. To the extent
supplies are available, the
PROVIDER or the PROVIDER SCIENTIST agrees to make the MATERIAL
available, under a
separate implementing letter to this Agreement or other
agreement having terms consistent with
the terms of this Agreement, to other scientists (at least those
at NONPROFIT
ORGANIZATION(S)) who wish to replicate the RECIPIENT SCIENTIST's
research; provided
-
Updated 12/17/07 sf
that such other scientists reimburse the PROVIDER for any costs
relating to the preparation and
distribution of the MATERIAL.
5.
(a) The RECIPIENT and/or the RECIPIENT SCIENTIST shall have the
right,
without restriction, to distribute substances created by the
RECIPIENT through
the use of the ORIGINAL MATERIAL only if those substances are
not
PROGENY, UNMODIFIED DERIVATIVES, or MODIFICATIONS.
(b) Under a separate implementing letter to this Agreement (or
an agreement at
least as protective of the PROVIDER's rights), the RECIPIENT may
distribute
MODIFICATIONS to NONPROFIT ORGANIZATION(S) for research and
teaching purposes only.
(c) Without written consent from the PROVIDER, the RECIPIENT
and/or the
RECIPIENT SCIENTIST may NOT provide MODIFICATIONS for
COMMERCIAL PURPOSES. It is recognized by the RECIPIENT that
such
COMMERCIAL PURPOSES may require a commercial license from
the
PROVIDER and the PROVIDER has no obligation to grant a
commercial license
to its ownership interest in the MATERIAL incorporated in
the
MODIFICATIONS. Nothing in this paragraph, however, shall prevent
the
RECIPIENT from granting commercial licenses under the
RECIPIENT's
intellectual property rights claiming such MODIFICATIONS, or
methods of their
manufacture or their use.
6. The RECIPIENT acknowledges that the MATERIAL is or may be the
subject of a
patent application. Except as provided in this Agreement, no
express or implied licenses or other
rights are provided to the RECIPIENT under any patents, patent
applications, trade secrets or
other proprietary rights of the PROVIDER, including any altered
forms of the MATERIAL made
by the PROVIDER. In particular, no express or implied licenses
or other rights are provided to
use the MATERIAL, MODIFICATIONS, or any related patents of the
PROVIDER for
COMMERCIAL PURPOSES.
7. If the RECIPIENT desires to use or license the MATERIAL or
MODIFICATIONS
for COMMERCIAL PURPOSES, the RECIPIENT agrees, in advance of
such use, to negotiate
in good faith with the PROVIDER to establish the terms of a
commercial license. It is
understood by the RECIPIENT that the PROVIDER shall have no
obligation to grant such a
license to the RECIPIENT, and may grant exclusive or
non-exclusive commercial licenses to
others, or sell or assign all or part of the rights in the
MATERIAL to any third party(ies), subject
to any pre-existing rights held by others and obligations to the
Federal Government.
8. The RECIPIENT is free to file patent application(s) claiming
inventions made by the
RECIPIENT through the use of the MATERIAL but agrees to notify
the PROVIDER upon filing
a patent application claiming MODIFICATIONS or method(s) of
manufacture or use(s) of the
MATERIAL.
-
Updated 12/17/07 sf
9. Any MATERIAL delivered pursuant to this Agreement is
understood to be
experimental in nature and may have hazardous properties. The
PROVIDER MAKES NO
REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND,
EITHER
EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES
OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE
USE
OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT,
TRADEMARK,
OR OTHER PROPRIETARY RIGHTS.
10. Except to the extent prohibited by law, the RECIPIENT
assumes all liability for
damages which may arise from its use, storage or disposal of the
MATERIAL. The PROVIDER
will not be liable to the RECIPIENT for any loss, claim or
demand made by the RECIPIENT, or
made against the RECIPIENT by any other party, due to or arising
from the use of the
MATERIAL by the RECIPIENT, except to the extent permitted by law
when caused by the
gross negligence or willful misconduct of the PROVIDER.
11. This agreement shall not be interpreted to prevent or delay
publication of research
findings resulting from the use of the MATERIAL or the
MODIFICATIONS. The RECIPIENT
SCIENTIST agrees to provide appropriate acknowledgement of the
source of the MATERIAL in
all publications.
12. The RECIPIENT agrees to use the MATERIAL in compliance with
all applicaple
statutes and regulations, including Public Health Service and
National Institutes of Health
regulations and guidelines such as, for example, those relating
to research involving the use of
animals or recombinant DNA.
13. This Agreement will terminate on the earliest of the
following dates: (a) when the
MATERIAL becomes generally available from third parties, for
example, though reagent
catalogs or public depositories or (b) on completion of the
RECIPIENT's current research with
the MATERIAL, or (c) on thirty (30) days written notice by
either party to the other, or (d) on
the date specified in an implementing letter, provided that:
(i) if termination should occur under 13(a), the RECIPIENT shall
be bound to the
PROVIDER by the least restrictive terms applicable to the
MATERIAL obtained from
the then-available resources; and
(ii) if termination should occur under 13(b) or (d) above, the
RECIPIENT will
discontinue its use of the MATERIAL and will, upon direction of
the PROVIDER, return
or destroy any remaining MATERIAL. The RECIPIENT, at its
discretion, will also either
destroy the MODIFICATIONS or remain bound by the terms of this
agreement as they
apply to MODIFICATIONS;
and
(iii) in the event the PROVIDER terminates this Agreement under
13(c) other
than for breach of this Agreement or for cause such as an
imminent health risk or patent
-
Updated 12/17/07 sf
infringement, the PROVIDER will defer the effective date of
termination for a period of
up to one year, upon request from the RECIPIENT, to permit
completion of research in
progress. Upon the effective date of termination, or if
requested, the deferred effective
date of termination, RECIPIENT will discontinue its use of the
MATERIAL and will,
upon direction of the PROVIDER, return or destroy any remaining
MATERIAL. The
RECIPIENT, at its discretion, will also either destroy the
MODIFICATIONS or remain
bound by the terms of this agreement as they apply to
MODIFICATIONS.
14. Paragraphs 6, 9, and 10 shall survive termination.
15. The MATERIAL is provided at no cost, or with an optional
transmittal fee solely to
reimburse the PROVIDER for its preparation and distribution
costs. If a fee is requested by the
PROVIDER, the amount will be indicated in an implementing
letter.
-
http://web.research.colostate.edu/osp/mta/pdf/UBMTALetter.pdf[2012/07/13
16:32:11]
Adobe XML
http://web.research.colostate.edu/osp/mta/pdf/UBMTALetter.pdf Adobe
XML
-
Updated 2/20/09 sf
UBMTA Implementing Letter The purpose of this letter is to
provide a record of the biological material transfer, to
memorialize the agreement between the PROVIDER SCIENTIST
(identified below) and the RECIPIENT SCIENTIST (identified below)
to abide by all terms and conditions of the Uniform Biological
Material Transfer Agreement (UBMTA) March 8, 1995, and to certify
that the RECIPIENT (identified below) organization has accepted and
signed an unmodified copy of the UBMTA. The RECIPIENT
organization's Authorized Official also will sign this letter if
the RECIPIENT SCIENTIST is not authorized to certify on behalf of
the RECIPIENT organization. The RECIPIENT SCIENTIST (and the
Authorized Official of RECIPIENT, if necessary) should sign both
copies of this letter and return one signed copy to the PROVIDER.
The PROVIDER SCIENTIST will forward the material to the RECIPIENT
SCIENTIST upon receipt of the signed copy from the RECIPIENT
organization. Please fill in all of the blank lines below: 1.
PROVIDER: Organization providing the ORIGINAL MATERIAL:
Organization:
Address:
2. RECIPIENT: Organization receiving the ORIGINAL MATERIAL:
Organization:
Address: 3. ORIGINAL MATERIAL (Enter description):
4. Termination date for this letter (optional): 5. Transmittal
Fee to reimburse the PROVIDER for preparation and distribution
costs
(optional). Amount:
-
Updated 2/20/09 sf
This Implementing Letter is effective when signed by all
parties. The parties executing this Implementing Letter certify
that their respective organizations have accepted and signed an
unmodified copy of the UBMTA, and further agree to be bound by its
terms, for the transfer specified above. PROVIDER SCIENTIST Name:
Title: Address:
Signature: Date: RECIPIENT SCIENTIST Name: Title: Address:
Signature: Date: RECIPIENT ORGANIZATION CERTIFICATION
Certification: I hereby certify that the RECIPIENT organization has
accepted and signed an unmodified copy of the UBMTA (May be the
RECIPIENT SCIENTIST if authorized by the RECIPIENT organization):
Authorized Official: Title: Address:
Signature: Date:
TextField1:
UBMTALetter.pdf
-
Updated 6/10/2010 sf
Biological Material Transfer Agreement I. Definitions
A. PROVIDER: Organization providing the ORIGINAL MATERIAL. The
name and address of this party will be specified on the MTA
Implementing Form.
B. PROVIDER SCIENTIST: The name and address of this party will
be specified on the MTA Implementing
Form.
C. RECIPIENT: Organization receiving the ORIGINAL MATERIAL. The
name and address of this party will be specified on the MTA
Implementing Form.
D. RECIPIENT SCIENTIST: The name and address of this party will
be specified on the MTA Implementing
Form.
E. ORIGINAL MATERIAL: The description of the material being
transferred will be specified on the MTA Implementing Form.
F. MATERIAL: ORIGINAL MATERIAL, PROGENY, and UNMODIFIED
DERIVATIVES. The
MATERIAL shall not include (a) MODIFICATIONS, or (b) other
substances created by the RECIPIENT through the use of the MATERIAL
which are not MODIFICATIONS, PROGENY, or UNMODIFIED
DERIVATIVES.
G. PROGENY: Unmodified descendant from the MATERIAL, such as
virus from virus, cell from cell, or
organism from organism.
H. UNMODIFIED DERIVATIVES: Substances created by the RECIPIENT
which constitute an unmodified functional subunit or product
expressed by the ORIGINAL MATERIAL. Some examples include:
subclones of unmodified cell lines, purified or fractionated
subsets of the ORIGINAL MATERIAL, proteins expressed by DNA/RNA
supplied by the PROVIDER, or monoclonal antibodies secreted by a
hybridoma cell line.
I. MODIFICATIONS: Substances created by the RECIPIENT which
contain/incorporate the MATERIAL.
J. COMMERCIAL PURPOSES: The sale, lease, license, or other
transfer of the MATERIAL or
MODIFICATIONS to a for-profit organization. COMMERCIAL PURPOSES
shall also include uses of the MATERIAL or MODIFICATIONS by any
organization, including RECIPIENT, to perform contract research, to
screen compound libraries, to produce or manufacture products for
general sale, or to conduct research activities that result in any
sale, lease, license, or transfer of the MATERIAL or MODIFICATIONS
to a for-profit organization. However, industrial sponsored
academic research shall not be considered a use of the MATERIAL or
MODIFICATIONS for COMMERCIAL PURPOSES per se, unless any of the
above conditions of this definition are met.
K. NON-PROFIT ORGANIZATION(S): A university or other institution
of higher education or an organization of the type described in
section 501(c)(3) of the Internal Revenue Code of 1954 (26 USC
501(c)) and exempt from taxation under section 501(a) of the
Internal Revenue Code (26 USC 501(a)) or any non-profit scientific
or educational organization, qualified under a state non-profit
organization statute. As used herein, the term also includes
government agencies.
-
Updated 6/10/2010 sf
II. Terms and Conditions of this Agreement
A. The PROVIDER retains ownership of the MATERIAL, including any
MATERIAL contained or incorporated in MODIFICATIONS.
B. The RECIPIENT retains ownership of: (a) MODIFICATIONS (except
that, the PROVIDER retains
ownership rights to the MATERIAL included therein), and (b)
those Substances created through the use of the MATERIAL or
MODIFICATIONS, but which are not PROGENY, UNMODIFIED DERIVATIVES,
or MODIFICATIONS (i.e., do not contain the ORIGINAL MATERIAL,
PROGENY, UNMODIFIED DERIVATIVES). If either 2(a) or 2(b) results
from the collaborative efforts of the PROVIDER and the RECIPIENT,
joint ownership may be negotiated.
C. The RECIPIENT and the RECIPIENT SCIENTIST agree that the
MATERIAL:
1. is to be used solely for teaching and academic research
purposes; 2. will not be used in human subjects, in clinical
trials, or for diagnostic purposes involving human
subjects without the written consent of the PROVIDER; 3. is to
be used only at the RECIPIENT organization and only in the
RECIPIENT SCIENTISTs
laboratory under the direction of the RECIPIENT SCIENTIST or
others working under his/her direct supervision; and
4. will not be transferred to anyone else within the RECIPIENT
organization without the prior written consent of the PROVIDER.
D. The RECIPIENT and the RECIPIENT SCIENTIST agree to refer to
the PROVIDER any request for the
MATERIAL from anyone other than those persons working under the
RECIPIENT SCIENTISTs direct supervision. To the extent supplies are
available, the PROVIDER or the PROVIDER SCIENTIST agrees to make
the MATERIAL available, under a separate implementing form, to this
Agreement or other agreement having terms consistent with the terms
of this Agreement, to other scientists (at least those at NONPROFIT
ORGANIZATION(S)) who wish to replicate the RECIPIENT SCIENTISTs
research; provided that such other scientists reimburse the
PROVIDER for any costs relating to the preparation and distribution
of the MATERIAL.
E. Distribution
1. The RECIPIENT and/or the RECIPIENT SCIENTIST shall have the
right, without restriction, to
distribute substances created by the RECIPIENT through the use
of the ORIGINAL MATERIAL only if those substances are not PROGENY,
UNMODIFIED DERIVATIVES, or MODIFICATIONS.
2. Under a separate implementing form to this Agreement (or an
agreement at least as protective of the PROVIDERs rights), the
RECIPIENT may distribute MODIFICATIONS to NONPROFIT ORGANIZATION(S)
for research and teaching purposes only.
3. Without written consent from the PROVIDER, the RECIPIENT
and/or the RECIPIENT SCIENTIST may not provide MODIFICATIONS for
COMMERCIAL PURPOSES. It is recognized by the RECIPIENT that such
COMMERCIAL PURPOSES may require a commercial license from the
PROVIDER and the PROVIDER has no obligation to grant a commercial
license to its ownership interest in the MATERIAL, incorporated in
the MODIFICATIONS. Nothing in this paragraph, however, shall
prevent the RECIPIENT from granting commercial licenses under the
RECIPIENTs intellectual property rights claiming such
MODIFICATIONS, or methods of their manufacture or their use.
F. The RECIPIENT acknowledges that the MATERIAL is or may be the
subject of a patent application.
Except as provided in this Agreement, no express or implied
licenses or other rights are provided to the RECIPIENT under any
patents, patent applications, trade secrets or other proprietary
rights of the PROVIDER, including any altered forms of the MATERIAL
made by the PROVIDER. In particular, no express or implied licenses
or other rights are provided to use the MATERIAL, MODIFICATIONS, or
any related patents of the PROVIDER for COMMERCIAL PURPOSES.
-
Updated 6/10/2010 sf
G. If the RECIPIENT desires to use or license the MATERIAL or
MODIFICATIONS for COMMERCIAL PURPOSES, the RECIPIENT agrees, in
advance of such use, to negotiate in good faith with the PROVIDER
to establish the terms of a commercial license. It is understood by
the RECIPIENT that the PROVIDER shall have no obligation to grant
such a license to the RECIPIENT, and may grant exclusive or
non-exclusive commercial licenses to others, or sell or assign all
or part of the rights in the MATERIAL to any third party(ies),
subject to any pre-existing rights held by others and obligations
to the Federal Government.
H. The RECIPIENT is free to file patent application(s) claiming
inventions made by the RECIPIENT through
the use of the MATERIAL, but agrees to notify the PROVIDER upon
filing a patent application claiming MODIFICATIONS or method(s) of
manufacture or use(s) of the MATERIAL.
I. Any MATERIAL delivered pursuant to this Agreement is
understood to be experimental in nature and may
have hazardous properties. The PROVIDER makes no representations
and extends no warranties of any kind, either expressed or implied.
There are no express or implied warranties of merchantability or
fitness for a particular purpose, or that the use of the MATERIAL
will not infringe any patent, copyright, trademark, or other
proprietary rights.
J. Except to the extent prohibited by law, the RECIPIENT assumes
all liability for damages which may arise
from its use, storage or disposal of the MATERIAL. The PROVIDER
will not be liable to the RECIPIENT for any loss, claim or demand
made by the RECIPIENT, or made against the RECIPIENT by any other
party, due to or arising from the use of the MATERIAL by the
RECIPIENT, except to the extent permitted by law when caused by the
gross negligence or willful misconduct of the PROVIDER.
K. This Agreement shall not be interpreted to prevent or delay
publication of research findings resulting from
the use of the MATERIAL or the MODIFICATIONS. The RECIPIENT
SCIENTIST agrees to provide appropriate acknowledgment of the
source of the MATERIAL in all publications.
L. The RECIPIENT agrees to use the MATERIAL in compliance with
all applicable statutes and regulations,
including Public Health Service and National Institutes of
Health regulations and guidelines such as, for example, those
relating to research involving the use of animals or recombinant
DNA.
M. This Agreement will terminate on the earliest of the
following dates: (a) when the MATERIAL becomes
generally available from third parties, for example, through
reagent catalogs or public depositories, or (b) on completion of
the RECIPIENTs current research with the MATERIAL, or (c) on thirty
(30) days written notice by either party to the other, or (d) on
the date specified in an implementing form, provided that: 1. if
termination should occur under M(a) above, the RECIPIENT shall be
bound to the PROVIDER by
the least restrictive terms applicable to the MATERIAL obtained
from the then-available sources; and 2. if termination should occur
under M(b) or (d) above, the RECIPIENT will discontinue its use of
the
MATERIAL and will, upon direction of the PROVIDER, return or
destroy any remaining MATERIAL. The RECIPIENT, at its discretion,
will also either destroy the MODIFICATIONS or remain bound by the
terms of this agreement as they apply to MODIFICATIONS; and
3. in the event the PROVIDER terminates this Agreement under
M(c) above other than for breach of this Agreement or for cause
such as an imminent health risk or patent infringement, the
PROVIDER will defer the effective date of termination for a period
of up to one year, upon request from the RECIPIENT, to permit
completion of research in progress. Upon the effective date of
termination, or if requested, the deferred effective date of
termination, RECIPIENT will discontinue its use of the MATERIAL and
will, upon direction of the PROVIDER, return or destroy any
remaining MATERIAL. The RECIPIENT, at its discretion, will also
either destroy the MODIFICATIONS or remain bound by the terms of
this agreement as they apply to MODIFICATIONS.
N. Paragraphs F, I, and J of these terms and conditions shall
survive termination.
-
Updated 6/10/2010 sf
O. The MATERIAL is provided at no cost, or with an optional
transmittal fee solely to reimburse the PROVIDER for its
preparation and distribution costs. If a fee is requested by the
PROVIDER, the amount will be indicated in an implementing form.
#### End of Agreement Terms and Conditions####
-
Updated 6/10/2010 sf
Biological Material Agreement Implementing Form The purpose of
this form is to provide a record of the biological material
transfer, to memorialize the agreement between the PROVIDER
SCIENTIST (identified below), and the RECIPIENT SCIENTIST
(identified below) to abide by all terms and conditions of the
accompanying Biological Material Transfer Agreement (BMTA), and to
certify that the RECIPIENT (identified below) organization has
accepted and signed an unmodified copy of the BMTA. The RECIPIENT
organizations Authorized Official also will sign this form if the
RECIPIENT SCIENTIST is not authorized to certify on behalf of the
RECIPIENT organization. The RECIPIENT SCIENTIST (and the Authorized
Official of RECIPIENT, if necessary), should sign two copies of
this form and return one signed copy to the PROVIDER (scanned
signatures are acceptable in lieu of two originals). The PROVIDER
SCIENTIST will forward the material to the RECIPIENT SCIENTIST upon
receipt of the signed copy from the RECIPIENT organization. This
Implementing Form is effective when signed by all parties. The
parties executing this Form certify that their respective
organizations have accepted and signed the copy of the BMTA,
initialing where modifications have been negotiated, and further
agree to be bound by the terms of the BMTA, for the transfer
specified above. Please fill in all of the blank lines below. 1.
ORIGINAL MATERIAL: (describe) 2. Optional Termination Date: 3.
Amount of Optional Transmittal Fee: (indicate currency) 4. PROVIDER
(Organization providing the ORIGINAL MATERIAL):
a. Name of Organization:
b. Street Address:
c. City/State/Zip+4:
d. Signature: Date:
5. PROVIDER SCIENTIST:
a. Name and Title:
b. Street Address:
c. City/State/Zip+4:
d. Signature: Date:
6. RECIPIENT SCIENTIST:
a. Name and Title:
b. Street Address:
c. City/State/Zip+4:
d. Signature: Date:
7. RECIPIENT ORGANIZATION CERTIFICATION (Organization receiving
the ORIGINAL MATERIAL):
I hereby certify that the RECIPIENT ORGANIZATION has accepted
and signed (initialing modifications) a copy of the BMTA.
a. Name of Organization:
b. Name and Title:
c. Street Address:
d. City/State/Zip+4:
e. Signature: Date:
-
http://web.research.colostate.edu/osp/mta/pdf/shortmta.pdf[2012/07/13
16:33:01]
Adobe XML
http://web.research.colostate.edu/osp/mta/pdf/shortmta.pdf
AdobeXML
-
Updated 6/10/2010 sf
Biological Material Transfer Agreement Colorado State University
(CSU)
Recipient Scientist: Recipient Organization: Recipient Address:
CSU's Provider Scientist: Provider's CSU Address: Regarding
Biological Material identified as: Biological Material to be used
for: In response to RECIPIENT'S request for the above-identified
Biological Material from Colorado State University (CSU), RECIPIENT
ORGANIZATION agrees to the following terms in consideration of
receipt of the Biological Material: 1. The above Biological
Material is the property of CSU and is made available as a service
to the Research community.
Biological Material shall mean the above-referenced Biological
Material plus progeny, unmodified derivatives, and any accompanying
know-how or data.
2. The Biological Material will not be further distributed to
others not affiliated with the RECIPIENT SCIENTIST'S laboratory
without the written permission of CSU. CSU reserves the right to
make the Biological Material available to others, both profit and
non-profit.
3. It is understood that no right to any license of the
Biological Material is given or implied by this Agreement. CSU's
name will be used for no endorsements.
4. The Biological Material will be used for research purposes
only. 5. If RECIPIENT SCIENTIST or RECIPIENT ORGANIZATION wishes to
patent or commercialize the Biological
Material or modifications, they will contact CSU prior to such
use to negotiate CSU's ownership interests. Ownership will be
negotiated in good faith by the parties hereto depending upon a)
their relative contribution to the creation of said modifications
and derivatives, and b) any applicable laws and regulations
relating to inventorship.
6. The Biological Material is experimental in nature and IT IS
PROVIDED WITHOUT ANY WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE.
7. The RECIPIENT SCIENTIST agrees to use the Biological Material
in compliance with all applicable Federal, State, and local
statutes and regulations. The Biological Material will not be used
for in vivo testing in human subjects.
The RECIPIENT SCIENTIST and the authorized representative from
the RECIPIENT ORGANIZATION will sign two copies to indicate
acceptance of the above terms. Two original signed documents should
be returned to CSU's PROVIDER SCIENTIST for signature and routed to
Sponsored Programs, 408 USC, Colorado State University, Ft.
Collins, CO 80523-2002 for PROVIDER ORGANIZATION signature (scanned
signatures are acceptable in lieu of two originals). Direct any
questions to 970-491-6355. CSU's PROVIDER SCIENTIST: Signature:
Date PROVIDER ORGANIZATIONS AUTHORIZED OFFICIAL: Signature: Date
RECIPIENT SCIENTIST: Signature: Date RECIPIENT ORGANIZATION
REPRESENTATIVE: NAME/TITLE: Signature: Date
CSU's PROVIDER SCIENTIST:
AUTHORIZED OFFICIAL:
RECIPIENT SCIENTIST:
NAME/TITLE:
TextField1:
shortmta.pdf
-
Colorado State University Material Transfer Agreement (MTA)
Information Sheet
1. Review the MTA. You need to be comfortable with the terms,
and know them well enough to abide by them. Sign the MTA only if
you find it acceptable. Flag questionable terms to the MTA
Administrators attention.
2. Complete this info sheet. 3. Send the MTA (all copies), AND
this sheet to Sponsored Programs, 2002 Campus Delivery. You may
send this info
sheet by email to the Sponsored Programs Senior Research
Administrator (SRA) assigned to your college
(http://web.research.colostate.edu/OSP/staff_detail.aspx) or by fax
(491-6147).
4. Call the SRA responsible for your college if you have
questions.
1. CSU person requesting or providing the material (MTAs must be
signed by a CSU non-temporary, salaried state classified employee,
administrative professional or faculty member). Please complete ALL
fields:
Name: Department:
Contact Info (email, phone & fax numbers):
Best way to contact you:
2. Organization providing the materials to CSU:
3. OR the organization receiving the materials from CSU:
4. Contact information at the outside organization: Name:
Contact Info (email, phone & fax numbers):
5. What materials are being transferred? Please give a brief
explanation, in laymens terms, of what these materials are (e.g., a
proprietary drug, a plasmid, a specific type of inhibitor, seed
type, etc.)
6. Is this material included on the current select agent and
toxin list? Yes No
7. What will you be doing with the materials? (n/a if you are
the provider of the material)
8. If the materials are being used in conjunction with a current
grant or contract, or if they involve materials or processes
developed with prior sponsorship, who is the sponsor and which
awards are involved?
n/a Sponsor: Award or 5-3 acct #:
9. Are there any conflicts between the terms of this MTA and
your current or past funding or other involved MTAs,
confidentiality agreements, or intellectual property agreements? If
yes, explain. (For example, a private company might require
confidentiality but the materials are used on a federal project
that cannot promise restricted access to results, or the materials
are used with other materials whose MTA terms conflict with this
one.)
Page 1 of 2 Updated 2/14/08 cc
-
Page 2 of 2 Updated 2/14/08 cc
Material Recipients must answer the questions below.
A. Research that involves any of the following requires approval
by the Institutional BioSafety Committee (IBC). Please answer each
item below. (IBC application forms, and information on exempt and
non-exempt rDNA can be found at
http://web.research.colostate.edu/ricro/ibc/ibc.aspx )
1. Does the material itself or the planned use of the material
involve infectious agents? Yes No
a) Have you already obtained IBC approval for the agent(s)? Yes
No
b) Is an import or export license required? Yes No
c) Have you obtained IBC project approval for the use of the
agent? Yes No If yes, please provide IBC project approval
number:
2. Does the material itself, or the planned use of the material,
involve human blood, body fluids or tissues? Yes No
If yes, please provide the IBC project approval number:
3. Does the material itself, or the planned use of the material,
involve recombinant DNA (excluding exempt experiments? Yes No
If yes, please provide the IBC project approval number:
B. If the use of the material will involve animals (research,
testing, teaching, breeding, and the like), please provide the
Animal Care and Use Committee (ACUC) approval number:
C. If the material will be used for human research, or was
collected from humans (cell lines, fluids, tissue samples), please
provide the Human Research Committee (HRC) approval number:
http://web.research.colostate.edu/ricro/ibc/ibc.aspx
-
AUTM | Master UBMTA Agreement Signatories
http://www.autm.net/Technology_Transfer_Resources/8199.htm[2012/07/13
16:33:35]
MEMBER CONNECT ABOUT AUTM ABOUT TECH TRANSFER EVENTS SURVEYS
& PUBLICATIONS MARKETPLACE
Home
About Tech Transfer
Technology Transfer
Resources
Public Benefits
Bayh-Dole Act
Links
Valuation Resources
White Papers
FAQs
AUTM Career Center
Techno-L
Network with AUTM
AUTM is a Member of
Home About Tech Transfer Tech Transfer Resources
Master UMBTA Agreement Signatories
1. Aarhus, University of, Lard Bolund, Doctor of Medical
Science, Chairman, 06/24/98
2. Academisch Medisch Centrum (Academic Medical Center),
Amsterdam, Prof. Dr. M.M. Levi, Chair of the Executive
Board and Dean, 06/12/12
3. AgResearch Ltd., Raakura Research Centre, Dr. Wayne Hein,
Animal Health Section Manager, 7/28/09
4. Alabama, University of, at Birmingham, Office of Grants and
Contracts Administration, Kenneth J. Roozen, PhD,
Executive VP, 04/26/95
5. Alabama, University of, The Board of Trustees of The
University of Alabama for and on behalf of its component
insitution, Donald J. Benson, Ph.D., Vice President for Reseach,
02/09/12
6. Alabama, University of, in Huntsville, The Board of Trustees
of the University of, Office of Technology
Commercialization, Lawrence R. Greenwood, PhD, Vice President
for Research, 02/20/06
7. Alaska, University of, Craig Dorman, Vice President for
Research, 12/02/04
8. Albany Medical College, Thomas J. Irwin, Director, Research
Administration, 09/28/04
9. Albert Einstein College of Medicine, Yeshiva University,
Sidney Goldfischer, M.D., Associate Dean for Scientific
Operations, 11/30/95
10. Alberta, The University of, Sharlene Coss, Contracts
Manager, 04/16/96
11. Allegheny-Singer Research Institute, Chet Cornman, Vice
President, 4/17/09
12. Arizona, University of, Michael A. Cusanovich, PhD, Vice
President for Research and Graduate Studies, 06/05/95
13. Arkansas State University, Dr. Elizabeth E. Hood, Vice
Chancellor for Research and Technology Transfer, 06/01/06
14. Arkansas, The Board of Trustees of the University of, Acting
on behalf of all Campuses, B. Alan Sugg, President,
03/26/98
15. Auburn University, C. Michael Moriarty, Associate Provost
and Vice President for Research, 06/06/98
16. Aurora Health Care, Inc., Randall Lambrecht, Ph.D., Vice
President Research and Academic Affairs, 08/24/11
17. AvidBiotics Corp., David Martin, CEO, 08/12/11
18. Ball State University, Thomas E. Spangler, Associate Vice
President for Finance and Assistant Treasurer, 06/28/06
19. Basel, University of, Prof. Dr. Peter Meier-Abt,
Vice-Rector, 02/09/11
20. Baylor College of Medicine, James W. Patrick, PhD, Vice
President and Dean of Research, 10/20/00
21. Baylor Research Institute, Bernard Brigonnet, CEO,
01/04/11
22. Baystate Health, Inc, Hal B. Jenson, MD, MBA, Chief Academic
Officer, 02/13/06
23. Beckman Research Institute of the City of Hope, Eric Jurrus,
PhD, Director, Office of Technology, 06/05/95
24. Behavioral Sciences Foundation, Frank Ervin, MD, President,
12/12/08
25. Benaroya Research Institute at Virginia Mason, Kelly
Moutsos, Grants & Contracts Manager, 02/08/05
26. Bern, University of, Dr. Daniel Odermatt, Director of
Administration, 5/31/10
27. Beth Israel Deaconess Medical Center, Mark Chalek, Director,
Office of Corporate Research, 07/01/99
28. Birmingham, University of, United Kingdom, Jean Hammersley,
Assistant Director of Finance, 03/11/03
29. Blood Center of Wisconsin and Blood Research Institute,
Gilbert C. White, II, M.D., Executive VP for Research,
09/22/11
30. Boehringer Ingelheim RCV GmbH & Co KG, Prof. Dr. Eric
Haaksma 04/23/12 and Dr. Erik Patzelt, 04/18/12
31. Boise State University, Mary Givens, Director Office of
Technology transfer, 01/07/11
32. Boston Baskin Cancer Group, PLC, d/b/a University of
Tennessee Cancer Institute, Phil Sydow, CEO, 01/07/11
33. Boston Biomedical Research Institute, Dr. Kathleen G.
Morgan, Sr. Scientist & Director, 05/16/95
34. Boston College, Stephen Erickson, Director, Office of
Research Administration, 04/20/95
35. Boston Medical Center Corporation, John Cragin, Associate
Director, Grants Administration, 07/02/01
36. Boston University, The Trustees of, Ashley J. Stevens,
Director, Office of Technology Transfer, 06/17/04
37. Bowling Green State University, Anthony M. Boccanfuso
(contact as of 02/25/04: Heinz Bulmann, Ph.D.), Vice Provost
for Research, 12/04/97
38. Boyce Thompson Institute for Plant Research, Inc., Joyce L.
Frank, Vice President for Operations, 11/04/98
39. Brandeis University, Joel M. Cohen, Assistant Provost for
Research, 12/04/97
40. Brigham and Women's Hospital, Shelby Calvert Morss, Vice
President, 05/23/95
41. British Columbia Cancer Agency Branch, Sarah Jane Lee,
Director, Technology Development Office, 9/16/08
42. British Columbia, University of, Richard D. Spratley,
Director, Research Services, 11/03/98
43. Brown University, Alice A. Tangredi-Hannon, Director, Office
of Research Administration, 08/29/95
44. Buffalo, The Research Foundation on behalf of University of,
Charles Kaars, Assistant Vice President, 02/24/03
AUTMGTP
Licensing
eGroups
MemberBlogs
http://community.autm.net/AUTM/AUTM/Home/Default.aspxhttp://community.autm.net/AUTM/AUTM/Home/Default.aspxhttp://www.autm.net/AM/Template.cfm?Section=Abouthttp://www.autm.net/AM/Template.cfm?Section=Abouthttp://www.autm.net/AM/Template.cfm?Section=Tech_Transferhttp://www.autm.net/AM/Template.cfm?Section=Tech_Transferhttp://www.autm.net/AM/Template.cfm?Section=Events1http://www.autm.net/AM/Template.cfm?Section=Events1http://www.autm.net/AM/Template.cfm?Section=Surveyshttp://www.autm.net/AM/Template.cfm?Section=Surveyshttps://www.autm.net/source/Orders/index.cfm?section=Marketplace&task=0&activesection=Ordershttps://www.autm.net/source/Orders/index.cfm?section=Marketplace&task=0&activesection=Ordershttp://www.autmfoundation.org/http://www.facebook.com/pages/Deerfield-IL/The-Association-of-University-Technology-Managers-AUTM/89207340918http://www.facebook.com/pages/Deerfield-IL/The-Association-of-University-Technology-Managers-AUTM/89207340918http://twitter.com/AUTM_Networkhttp://twitter.com/AUTM_Networkhttp://www.linkedin.com/groups?gid=66625&trk=anetsrch_name&goback=.gdr_1250611247485_1http://www.linkedin.com/groups?gid=66625&trk=anetsrch_name&goback=.gdr_1250611247485_1http://www.attp.info/http://www.autm.net/AM/template.cfm?section=homehttp://www.autm.net/AM/Template.cfm?Section=Tech_Transfer&Template=/CM/HTMLDisplay.cfm&ContentID=2979http://www.autm.net/AM/Template.cfm?Section=Technology_Transfer_Resources1&Template=/CM/HTMLDisplay.cfm&ContentID=7886http://www.autm.net/AM/Template.cfm?Section=Technology_Transfer_Resources1&Template=/CM/HTMLDisplay.cfm&ContentID=7886http://www.autm.net/AM/Template.cfm?Section=Public_Benefits&Template=/CM/HTMLDisplay.cfm&ContentID=7863http://www.autm.net/AM/Template.cfm?Section=Bayh_Dole_Act&Template=/CM/HTMLDisplay.cfm&ContentID=7698http://www.autm.net/AM/Template.cfm?Section=Links&Template=/CM/HTMLDisplay.cfm&ContentID=2341http://www.autm.net/AM/Template.cfm?Section=Valuation_Resources_Valuate&Template=/CM/ContentDisplay.cfm&ContentID=1381http://www.autm.net/AM/Template.cfm?Section=White_Papers&Template=/CM/HTMLDisplay.cfm&ContentID=3754http://www.autm.net/AM/Template.cfm?Section=FAQs&Template=/CM/HTMLDisplay.cfm&ContentID=2186http://www.jobtarget.com/home/index.cfm?site_id=3719http://www.autm.net/AM/Template.cfm?Section=Techno_L&Template=/CM/HTMLDisplay.cfm&ContentID=6690http://www.autm.net/AM/http://www.autm.net/AM/Template.cfm?Section=Tech_Transferhttp://www.autm.net/AM/template.cfm?section=homehttp://gtp.autm.net/http://gtp.autm.net/http://gtp.autm.net/http://gtp.autm.net/http://www.autm.net/source/NinePoints/ninepoints_endorsement.cfmhttp://www.autm.net/source/NinePoints/ninepoints_endorsement.cfmhttp://www.autm.net/source/NinePoints/ninepoints_endorsement.cfmhttp://community.autm.net/AUTM/AUTM/Discussions/AllDiscussions/Default.aspxhttp://community.autm.net/AUTM/AUTM/Discussions/AllDiscussions/Default.aspxhttp://community.autm.net/AUTM/AUTM/Discussions/AllDiscussions/Default.aspxhttp://community.autm.net/AUTM/AUTM/Blogs/ViewBlogs/Default.aspxhttp://community.autm.net/AUTM/AUTM/Blogs/ViewBlogs/Default.aspxhttp://community.autm.net/AUTM/AUTM/Blogs/ViewBlogs/Default.aspxhttp://community.autm.net/AUTM/AUTM/Blogs/ViewBlogs/Default.aspx
-
AUTM | Master UBMTA Agreement Signatories
http://www.autm.net/Technology_Transfer_Resources/8199.htm[2012/07/13
16:33:35]
45. California, The Regents of the University of, Office of
Technology Transfer, Terence A. Feuerborn, Executive Director,
06/30/95
46. California, University of, at Santa Cruz, Office of
Sponsored Programs, William Clark, Director, 02/02/00
47. California Institute of Technology, Lawrence Gilbert,
Director of Technology Transfer, 01/30/96
48. California Pacific Medical Center, David R. Fielder, Vice
President, Research, 02/12/98
49. Cambridge University, Martin Reavley, Director, 09/21/10
50. Cardiff University, Geraint Jones, Director, Research and
Commercial Division, 03/28/06
51. Carilion Medical Center, Daniel Harrington, MD, Vice
President, Academic Affairs, 6/19/09
52. Carnegie Institution of Washington, John J. Lively, Director
of Administration and Finance, 03/23/04
53. Carnegie Mellon University, Susan L. Burkett, Associate
Provost for Research and Academic Administration, 08/20/03
54. Case Western Reserve University, Richard A. Zdanis, Provost
& University Vice President, 07/29/98
55. Cedars-Sinai Medical Center, Shlomo Melmed, Daniel M.
Oshiro, Senior Vice President for Academic Affairs,
56. Central Florida, University of, John Miner, Licensing
Associate, 7/27/09
57. Centre for Addiction & Mental Health, Dr. Shitij Kapur,
Vice President Research, 07/19/04
58. Centre Hospitalier Universitaire De Quebec,Rene Rouleau,
Director General, CHUQ, 11/3/08, Jean-Claude Forest,
Director, CRCHUQ, 10/28/08
59. Centre National de la Recherche Scientifique (CNRS),
Philippe Pieri, Regional Delegate of the CNRS-Alsace
Delegation, 01/06/09
60. Chicago, The University of, Mary Ellen Sheridan, Assistant
Vice President for Research, 05/25/95
61. Children's Hospital & Research Center at Oakland,
Antonie H. Paap, President & CEO, 08/16/04
62. Children's Hospital Los Angeles, Nick Goodman, Director,
Corporate Relations and Technology Transfer, 04/02/03
63. Children's Hospital of Philadelphia, Robert G. Uris, Vice
President, Research, 08/04/98
64. Children's Hospital, Boston, Intellectual Property Office,
Donald P. Lombardi, Director, 02/17/00
65. Children's Hospital, Boston, Brenda Manning, Senior
Licensing Manager, 05/05/06
66. Chinese University of Hong Kong, The, Mrs. Alice Ngan Yip,
Director, Research and Technology Administration Office,
09/06/02
67. Cincinnati Children's Hospital Medical Center, David N.
Glass, M.D., Associate Director, CCRF, 03/03/08
68. Cincinnati, University of, Norman M. Pollack, PhD, Director
& Intellectual Property and University Pa, 04/19/95
69. City of Hope National Medical Center, Office of Technology
Transfer, Eric Jurrus, PhD, Director, 05/30/95
70. Clark University, Richard P. Traina, PhD, President,
08/29/95
71. Clemson University, Y.T. Shah, Chief Research Officer and
Senior Vice Provost, 10/12/98
72. Cliniques Universitaires St. LUV (UCL), J. Melin, Medical
Director, General Coordinator, 09/17/10
73. CNRS, Neurobiologie Cellulaire et Moleculaire, Dr. Gerard
Baux, Director of Laboratory Neurobiologie Cellulaire et
Moleculaire, 01/27/03
74. Cold Spring Harbor Laboratory, Office of Technology
Transfer, John Maroney, Director, 03/12/01
75. College of the Holy Cross, Rev. John E. Brooks, President
Emeritus, 08/25/95
76. College of William and Mary, Jason P. McDevitt, Director,
Technology Transfer, 9/25/09
77. Colorado, University of, System Technology Transfer, Ken
Porter, Ph.D., Director of Licensing, and David N. Allen,
Ph.D., Associate Vice President for Technology Transfer,
12/05/05
78. Colorado Seminary (dba: The University of Denver), Margaret
Henry, Controller, 02/09/12
79. Colorado State University System, acting by and through
Colorado State University, Sponsored Programs, Anthony
Frank, Ph.D., Vice President Research and Information
Technology, 08/20/04
80. Concordia University, Dr. Carole Brabant, Acting Director,
Office of Research, 11/17/09
81. Connecticut, University of, Health Center, Leonard P.
Paplauskas, Assistance Vice President for Research, 05/09/95
82. Connecticut, University of, Thomas G. Giolas, Vice Provost
for Research and Graduate Education, 08/05/97
83. Cornell University, Norman R. Scott, VP for Research and
Advanced Studies, 10/07/95
84. Creighton University, Kathleen Taggart, Associate Vice
President for Research and Compliance, 12/17/10
85. CSIR Biosciences, Dr. Rchikwamba, 08/11/11
86. CSIRO Plant Industry, Richard Steele, Contracts Officer,
04/06/00
87. Dana-Farber Cancer Institute, Office of Technology Transfer,
Ruth Emyanitoff, PhD, Director, 05/02/01
88. Delaware, University of, Costel D. Denson, Vice Provost for
Research, 04/21/95
89. Department of Molecular Biology, The Institute of Basic
Medicine, Chinese PLA General Hospital, Weidong Han,
Associated Professor, 08/08/06
90. Doheny Eye Institute, Ronald E. Smith, M.D., Vice President,
07/26/96
91. East Carolina University, Martha J. S. Van Scott, Director,
Office of Technology Transfer, 03/24/04
92. Eastern Virginia Medical School, Robert F. Williams, Ph.D.,
M.B.A., Director, Office of Technology Transfer, 07/29/03
93. Emory University, Nancy L. Wilkinson, M.P.H., Assistant VP
for Research, 10/03/96
94. Ernest Gallo Clinic and Research Center, William R. Sawyers,
Chief Administrative Officer, 5/15/09
95. Florida State University, Kirby W. Kemper, Vice President
for Research, 9/8/09
96. Florida, University of, Karen A. Holbrook, Vice President
and Dean, 08/04/95
97. Forsyth Institute, Richard L. Pharo, Sc.D., Executive Vice
President, 08/11/06
98. Fox Chase Cancer Center, Frances Galvin, Assistant Director,
Business Development, 05/17/01
99. Fred Hutchinson Cancer Research Center, Technology Transfer,
Catherine J. Hennings, Director, 10/19/95
-
AUTM | Master UBMTA Agreement Signatories
http://www.autm.net/Technology_Transfer_Resources/8199.htm[2012/07/13
16:33:35]
100. Fukuoka University Faculty of Medicine, Mesahide Kuroki,
M.D., Ph.D.,Dean, 12/02/10
101. Fundacion Progreso Y Salud, Office of Technology Transfer,
Rafael Camacho Fumanal, Director OTT-APHS,
08/11/2006
102. General Hospital of Jinan Military Area, Thoracic Surgery,
Lu Zhaotong, Professor and Director, 01/26/02
103. Geneva, University of, Jean-Luc Veuthey, Vice-Rector,
11/02/11
104. GenoCell LLC, Rick Roth, Chief Operating Officer,
07/21/05
105. George Washington University, The, Astra Bain-Dowell,
Assistant Vice President for Health Research, Compliance and
Technology Transfer, 09/28/01
106. George Washington University, The, Astra Bain-Dowell, Asst.
VP for Health Research, Compliance & Technology
Transfer, 09/28/01
107. Georgetown University, Carol L. Tracy (Updated contact as
of 8/5/02: Martin A. Miller, Vice President for Technology
Transfer), Esq., Director of Technology Transfer, 10/04/95
108. Georgia State University, Robin Morris, PhD, Vice President
of Research, 9/29/07
109. Georgia, University of, Joe L. Key, Vice President for
Research, 02/12/97
110. Georgia, University of, Research Foundation, Inc., Joe L.
Key, Executive Vice President, 02/12/97
111. Georgia Tech Research Corporation, Jilda D. Garton,
Associate Vice Provost for Research, 09/03/99
112. Girona, University of, Cardiovascular Genetics Center,
Guillermo Lavier Perez, Ph.D., 07/10/09. Institutionwithraw
acceptance as of 11/14/11
113. Girona, University of, Cardiovascular Genetics Center,
11/14/11
114. Granada, University of, Jesus Chamorro, Deputy-Chancellor,
06/15/12
115. Guangzhou Institute of Energy Conversion, Chinese Academy
of Sciences, Yuan Zhen-Hong, Chief Scientist, Dean of
Lab of Biomass Energy Bioconversion, 02/06/07
116. Guelph, University of, Dept. of Environmental Biology, J.
Christopher Hall, Ph.D., Professor, 07/15/03
117. Gundersen Lutheran Medical Foundation, William Agger, MD,
Director of Research, 11/11/09
118. H. Lee Moffitt Cancer Center and Research Institute, James
Mul, Ph.D., ACD, Translational Research/Tech
Development, 09/26/03
119. Harbin Medical University, Department of Pharmacology,
Prof. Guoften Qiao, Vice Director, 11/12/10
120. Harvard College, President and Fellows of, Awards
Management and Resource Information, Patricia Tucker, Director,
03/07/95
121. Hawaii, University of, Office of Technology Transfer and
Economic Develop, Richard F. Cox, Jr. (Original Signatory
was Glenn K. Nakamura), Director, 06/26/98
122. Hebrew University of Jerusalem, Dr. Eran Vardi, Director,
Authority for Research and Development, 04/06/10
123. Henry Ford Health System, Nancy J. Hay, MHSA, Director of
Research, 01/19/12
124. Het Antoni van Leeuwenhoek Ziekenhuis, Professor A. J. M
Berns, Director of Research, 10/14/09
125. Hokkaido University, Grad. Sch. Pharm. Sci., Hideyoshi
Yokosawa, Ph.D., Dean, 06/25/06
126. Hong Kong University of Science and Technology, Technology
Transfer Center, Roland T. Chin, Vice-President for
Research and Development, 11/12/03
127. Hospital for Sick Children, The, Contracts Office, Anitra
Sisavang, Coordinator, 11/11/05
128. House Ear Institute, David J. Lim, MD, Executive Vice
President, Research, 09/09/05
129. Houston, University of, Elizabeth Anderson-Fletcher,
Associate Vice Chancellor/Vice President for Research and
Technology Transfer, 05/16/11
130. Howard Hughes Medical Institute, Jack Dixon, Ph.D., Vice
President and Chief Scientific Officer, 05/09/07
131. Humboldt University, Institute of Biology, Thomas J.
Buckhout, Professor, Institute Director, 09/09/99
132. Iceland, University of, Agust H. Ingporsson, Director,
Research Liaison Office, 02/03/11
133. Idaho, University of, Charles R. Hatch, Vice President for
Research and Graduate Studies, 03/21/01
134. Illinois, Board of Trustees of the University of, Craig S.
Bazzani, Comptroller, 03/11/98
135. Illinois at Urbana-Champaign, University of, Research and
Technology Management Office, Melvin J. DeGeeter, PhD,
Director, 10/10/95
136. Illinois University at Carbondale, SIUC, John S. Jackson
IIII, Vice Chancellor for Academic Affairs and Provost for Jo
Ann Argersinger, Chancellor, 01/22/99
137. Immune Disease Institute, Inc., Ryan M. Dietz, Director,
Office of Technology Development, 8/18/10
138. Imperial College of Science, Technology and Medicine,
Mirabell Nsofor, Contracts Officer-MTAs, 12/14/11
139. Indiana University, Technology Transfer Office, Dr. Melvin
J. DeGeeter, Director, 07/05/95
140. Institut fur Molekulare (IMBA), Dr. Josef Penninger,
Director, 06/07/04
141. Institut fur Pharmazeutische Biologie der Rheinischen,
Friedrich-Wilhelms-Universitat Bonn, Dr. E. Leistner,
Professor,
Geschaftsfuhrender Direktor, 01/09/97
142. Institut fur Vegetative Physiologie, Prof. Dr. med. G.
Pfitzer, Director, 3/8/10
143. Institut National de la Recherche Scientifique (INRS),
Alain Fournier, PhD., Interim Director, INRS-Institut Armand-
Frappier, 08/09/06
144. Institut Pasteur Korea, Dr. Olf Nehrbass, CEO, 1/20/10
145. Institute for Animal Health, Richard Shaw, Director of
Operations, 06/01/12
146. Institute for Biological Energy Alternatives, Inc., J.
Craig Venter, Ph.D., President, 09/10/03
147. Institute for Brain Research, Dr. Hans Lassmann, Professor
and Director, 05/22/02
148. Institute for Genomic Research, William C. Nierman, PhD,
Vice President for Research, 05/21/99
149. Institute for Hygiene and Infectious Diseases in Animals,
Justus Liebig University of Giessen, Georg Baljer, Professor
-
AUTM | Master UBMTA Agreement Signatories
http://www.autm.net/Technology_Transfer_Resources/8199.htm[2012/07/13
16:33:35]
Dr. habil., Head of Institute, 09/20/06
150. Institute for Systems Biology, Leroy E. Hood, MD, PhD,
President, Director and Professor, 05/02/01
151. Institute of Biochemistry and Cell Biology (IBCB), Fudi Ni,
Director of Academic Administration Department, IBCB,
07/07/05
152. Institute of Botany, Chinese Academy of Sciences, Kang
Chong, Professor, 8/31/2009
153. Institute of Chemical Technology, G.D. Yadou, Professor,
Vice Chancellor, ICT, 02/24/12
154. Institute of Paper Science and Technology, Gary A. Baum,
Vice-President of Research and Academic Affairs, 04/22/99
155. Institute of Plant Biology, China, Wu Ping, Executive
Deputy Dean of Life Science College, 01/27/00
156. Institute of Science and Technology Austria (IST), Thomas
A. Henzinger, President, 02/11
157. Integrated Biobank of Luxembourg (IBBL), Dr. Jean-Claude
Schmit, President of the Governing Board, 4/27/10
158. International University Bremen GmbH, Dr. Alexander
Ziegler-Jons, Vice President University Development, 11/29/06
159. Iowa State University, Richard E. Hasbrook (contact as of
2/27/03 Thane Peterson), Contracts and Grants Officer,
08/18/99
160. Iowa State University Research Foundation, Inc., Original
signatory: Alan S. Paau (contact as of 2/12/03: Ken
Kirkland), Executive Director, 01/16/96
161. Iowa, University of, Twila Fisher Reighley, Vice President
for Research, 12/16/05
162. IUT de Quimper, Adrien Binet, Professor, 06/05/98
163. J. Craig Venter Institute, Inc., (Updated 12/13/04 -
Formerly listed as Center for the Advancement of Genomics,
Inc.),
9704 Medical Center Drive, Rockville, MD 20850
164. J. Craig Venter/Marvin Frazier (Updated 12/13/04), Ph.D.,
President/Vice President, Research (Updated 12/13/04),
09/10/03
165. J. Craig Venter Science Foundation Joing Technology Center,
Inc., J. Craig Venter, Ph.D., President, 09/10/03
166. J. David Gladstone Institutes, Joan Bruland, Intellectual
Property Counsel, 07/08/02
167. Jackson Laboratory, The, David Einhorn, Esq., House
Counsel, 01/10/96
168. Johns Hopkins University, Theodore O. Poehler, PhD, Vice
Provost for Research, 04/29/98
169. Johns Hopkins University School of Medicine, David A.
Blake, PhD, Executive Vice Dean, 05/31/95
170. Joslin Diabetes Center, Carl S. Finn, General Counsel,
08/04/03
171. Juntendo University School of Medicine, Yasuhiko Tomino,
Dean, 04/06/10
172. Kansas, University of, Steven F. Warren, PhD, Vice Provost
for Research and Graduate Studies, 11/14/08
173. Kansas State University, Paul R. Lowe, Assistant Vice
Provost for Research, 03/22/99
174. Kansas Center For Research, Inc., University of, Barbara
Armbrister, Director, 07/02/07
175. Kansas Medical Center, University of, Ted Knous, Ph.D.,
Vice Chancellor for Research Administration, 08/23/05
176. Katholieke Universiteit Leuven, Research & Development,
Oliver Lescroart, IPR-Officer, 08/17/06
177. Keio University, Institute for Advanced Biosciences, Masaru
Tomita, Ph.D., General Director, 10/04/06
178. Kent State University, Research and Graduate Studies,
Eugene P. Wenninger, Vice Provost and Dean, 05/10/95
179. Kentucky Space LLC, Kris Kimel, President, 04/14/11
180. Kentucky, University of, Donald G. Keach, Director,
Intellectual Property Development, 08/21/01
181. Lawson Health Research Institute, Sandra Mochodo, Manager,
Grants and Contracts, 01/31/06
182. La Jolla Institute for Allergy and Immunology, Charles A.
Carpowich, Jr., Chief Operating Officer, Amy M. Klepsch,
Manager, Intellectual Property, 11/16/01
183. Lausanne, University of, Prof. Patrick Francioli, Dean of
the Biology and Medicine Faculty, 05/9/10
184. Lehigh University, Office of Technology Transfer,
Entrepreneurial Research and Education, Glenn J. Doell,
09/29/06
185. Leland Stanford Junior University, Board of Trustees of,
Stefani Shek, Industrial Contacts Associate, 5/19/09
186. Loma Linda Veterans Association for Research and Education,
Gayle Rundberg, Executive Director, 05/30/03
187. Los Angles Biomedical Research Institute at Harbor-UCLA
Medical Center, L. Jean Remmer, Assistant Vice President,
Research Administration, 6/24/08
188. Louisiana State University, Board of Supervisors of acting
on behalf of the University of New Orleans, Agricultural and
Mechanical College, Mary Louise Trammell, PhD, Associate Vice
Chancellor for Research and Director of Technology
Transfer, 10/15/97
189. Louisiana State University and A&M College, The Board
of Supervisors of, H. Douglas Braymer, VP for Academic
Affairs and Technology Transfer, 10/13/95
190. Louisiana State University Health Sciences Center -
Shreveport, Robert A. Barish, M.D., M. B. A., Chancellor,
04/28/2010
191. Louisville, University of, Nancy C. Martin, Vice President
for Research, 03/06/97
192. Lovelace Respiratory Research Institute, Chris
Merriam-Leith, Director of Business Affairs, 07/21/11
193. Loyola University Chicago, David S. Crumrine, Associate
Directory, Research Services, 03/29/00
194. Lund, University of, Department of Cell and Molecular
Biology, Charlotte Erlanson-Albertsson, Ph.D., Professor,
10/06/03
195. Maine Medical Center Research Institute, James W. Donovan,
Associate Vice President for Medical Affairs, 11/14/03
196. Manchester, University of, Research Office, Karen Shaw,
Head of the Research Office, 09/21/10
197. Manitoba, University of, T.G. Falconer, Vice President
(Administration), 10/25/95
198. Mario Negri Institute, Prof. Silvio Garattini, Director,
9/22/09
199. Marshfield Clinic Research Foundation, A Division of
Marshfield Clinic, Steve Wesbrook, Ph.D., Deputy Director,
02/25/09
-
AUTM | Master UBMTA Agreement Signatories
http://www.autm.net/Technology_Transfer_Resources/8199.htm[2012/07/13
16:33:35]
200. Maryland, University of, at Baltimore, Office of Sponsored
Programs Administration, Marjorie Forster, Director, 06/27/95
201. Maryland, University of, at Baltimore County, Dr. Michael
Breton, Assistant Vice Provost for Research, 09/11/98
202. Maryland, University of, at College Park, Antoinette
Lawson, Associate Director, 10/12/11
203. Massachusetts Eye and Ear Infirmary, Office of Research
Administration, Elayn G. Byron, CRA, Director, 04/26/04
204. Massachusetts General Hospital, Licensing and Industry
Sponsored Research, Marvin C. Guthrie, JD, VP, Patents,
04/24/95
205. Massachusetts Institute of Technology, Technology Licensing
Office, Lita L. Nelsen, Director, 04/26/95
206. Massachusetts Medical School, University of, Office of
Technology Management, James P. McNamara, Ph.D.,
Executive Director, OTM, 10/05/05
207. Massachusetts Medical School, University of, Peter E.
Newburger, MD, Professor of Pediatrics and Cancer Biology,
04/05/06
208. Massachusetts, University of, Commercial Ventures &
Intellectual Property, William S. Rosenberg, Ph.D., Executive
Director, CVIP, 10/07/05
209. Max-Delbruck-Centrum Fur Molekulare Medizin (MDC),
Christine Rieffel-Braune, Head of Legal Department &
Technology Transfer, 12/15/11
210. Max Planck Florida Corporation/ Max Planck Florida
Institute, Dr. Ivan C. Baines, Chief Operating Officer,
02/16/11
211. Max Planck Institute of Molecular Cell Biology and
Genetics, Anthony A. Hyman, Director, 05/12/05
212. Max Planck Institute for Developmental Biology, Dr. Detlef
Weigel, Executive Director, 9/10/09
213. Mayo Clinic Arizona, (current contact as of 5/23/12,
Virginia M. Bruce, Director, Legal Contract Administration), Mary
J.
Hoffman, Secretary & Assistant Treasurer, 03/26/97
214. Mayo Clinic Jacksonville (current contact as of 5/23/12,
Virginia M. Bruce, Director, Legal Contract Administration),
Jeffrey Scheffel, Chair Division of Research Services,
09/22/06
215. Mayo Clinic, (c(current contact as of 5/23/12, Virginia M.
Bruce, Director, Legal Contract Administration), Bonnie
Edwards, Assistant Treasurer, 11/24/00
216. Mayo Foundation for Medical Education and Research,
(current contact as of 5/23/12, Virginia M. Bruce, Director,
Legal Contract Administration), Rick F. Colvin, Assistant
Treasurer, 06/30/97
217. McGill University, McGill University Health Centre (MUHC),
Office of Technology Transfer, Alex Navarre, Director,
Office of Technology Transfer, 10/12/03
218. Medical Center of Central Massachusetts, Peter H. Levine,
MD, President and CEO, 08/30/95
219. Medical College of Georgia, School of Graduate Studies,
Matthew J. Kluger, PhD. MBA, Vice President for Research
and Dean, 07/26/99
220. Medical College of Pennsylvania Hahnemann University,
Kathleen A. Denis, PhD, Vice President, Technology
Development, 10/12/95
221. Medical University of South Carolina, Dillard C. Marshall,
Director, Research Administration, 11/01/95
222. Medicine and Dentistry, New Jersey, University of,
Frederick J. Hammond, Jr., Senior VP for Administration and
Finance, 09/05/95
223. Medizin Universitat Innsbruck, Innsbruck, Austria, Dr.
Gunther Speru, Vice-Rector Research, Dr. Sonja Schmidl, Head
of the Leagal Department, 03/05/11
224. Memorial Sloan-Kettering Cancer Center and Memorial
Sloan-Kettering Institute for Cancer Research, Andrew D.
Maslow, Director, Office of Industrial Affairs, 11/18/05
225. Memphis, University of, Andrew Meyers, Ph.D., Vice Provost
for Research, 8/16/10
226. Miami, University of, Robert W. Rubin, Vice Provost for
Research, 03/19/96
227. Michigan State University, Norman M. Pollack, PhD,
Assistant Vice President for Intellectual Property, 11/13/01
228. Michigan Technological University, (current contact as of
11/21/01: Dr. David D. Reed, VP for Research), Dr. Sung M.
Lee, Vice Provost for Research, 05/02/96
229. Michigan, University of, Division of Research Development
& Administration, Marvin G. Parnes, Associate Vice
President for Research, 10/13/00
230. Minnesota, Univ of, Office of Research & Technology
Transfer, Orig. Signatory: A.R. Potami, Associate Vice
President,
Current Contact: Tony Strauss, Acting Assistant Vice President,
07/20/95
231. Mississippi State University, Richard Swann, Director,
Sponsored Programs Administration, 5/21/10
232. Mississippi, University of, Ronald F. Borne, Interim Vice
Chancellor for Research, 05/18/00
233. Missouri, University of, at Columbia, Office of Sponsored
Prog. Administration, Richard J. Otto, Director, 06/13/95
234. Missouri, University of, at Kansas City, Edgar J. Ellyson,
PhD, Director, Grants & Contracts, 06/08/95
235. Missouri, University of, at Rolla, Dr. Walter J. Gajda,
Jr., Vice Chancellor for Academic Affairs, 06/30/95
236. Missouri, University of, at St. Louis, Dr. Douglas Wartzok,
Associate Vice Chancellor for Research, and Graduate
Dean, 05/17/95
237. Monash University, Rocco Iannello, Business Development
Manager, 10/14/10
238. Montana State University, Rebecca W. Mahurin, Ph.D,
Director, Technology Transfer, 1/14/08
239. Mount Sinai Hospital, Samuel Lunenfeld Research Institute,
Patents and Licensing, Terry Donaghue, Manager,
05/02/95
240. Mount Sinai School of Medicine, Office of Technology &
Business Development, Kathleen P. Mullinix, Ph.D., 12/07/10
241. Institute for Cellular and Molecular Biology, Robert M.
Krug, Ph.D., Professor, 09/06/06
242. National Chung Hsing University, Ru-Jong Jeng, 07/17/06
243. National Medial Center, Dr. Balazs Sarkadi, Scientific Vice
Director, 10/25/2006
244. National Institute of Dental and Craniofacial Research
(NIDCR), David W. Bradley, Ph.D., Technology Development
Coordinator, 10/31/11
-
AUTM | Master UBMTA Agreement Signatories
http://www.autm.net/Technology_Transfer_Resources/8199.htm[2012/07/13
16:33:35]
245. National Institutes of Health, LBC, Dr. Albert Fornace,
Acting Chief, 03/26/97
246. National University of Ireland, Galway, Daniel O'Mahony,
Director, Technology Transfer, 02/16/06
247. National University of Ireland Maynooth, Prof. Ray O'Neill,
Vice president for Research, 05/31/12
248. National University of Singapore, Irene Cheong, Director,
Industry Liaison Office, 10/27/10
249. Nebraska-Lincoln, University of, David Conrad, Associate
Vice Chancellor for Technology Development, 10/12/08
250. Nebraska, University of, Medical Center, William O. Berndt,
PhD, Vice Chancellor for Academic Affairs, 03/08/00
251. Nanyang Technological University, Yehuda Yarmut, Director,
Enterprise & Technology Development, Nanyang
Innovation & Enterprise Office, 01/18/11
252. Nevada Cancer Institute, Meredith Mullins, Associate Center
Director, Sr. Vice President, Research Operations and
Research Administration, 01/25/10
253. Nevada, University of at Las Vegas, Dr. Paul W. Ferguson,
Vice President for Research and Graduate Studies,
03/27/06
254. Nevada, University of, Reno, Technology Transfer Office,
Ryan A. Heck, J.D., Ph.D., Patent Counsel and Director,
02/25/10 and Daniel Klaich, Chancellor, Board of Regents of the
Nevada System of Higher Education on behalf of the
University of Nevada, Reno, 11/08/11
255. Newcastle University, Dr. Amanda Gregory, Grants and
Contracts Manager, 01/26/10
256. New England Deaconess Hospital, David Kiszkiss, VP,
Research, 05/01/95
257. New England Medical Center Hospitals, Inc., Technology
Administration, Fred Reinhart, Director, 09/11/95
258. New Hampshire, University of, Kathryn B. Cataneo, Executive
Director, 03/31/99
259. New Jersey Institute of Technology, Dr. Raquel
Perez-Castillejos, Assistant Professor, 12/9/2008
260. New Jersey Institute of Technology, Donald H. Sebastian,
Sr. VP for Research and Development, 12/8/08
261. New Mexico, University of, Nasir Ahmed, PhD, Associate
Provost for Research, 06/12/00
262. New York Medical College, Catharine Crea, Associate Dean
for research Administration, 01/04/11
263. NIMH, Robert M. Cohen, PhD, MD, Lead Clinical Investigator,
08/22/97
264. North Carolina at Chapel Hill, University of, Technology
Development, Francis J. Meyer, Associate Vice Chancellor &
Director, 10/04/95
265. North Carolina Central University, James H. Ammons,
Chancellor, 06/08/04
266. North Carolina State University, Dr. David Winwood,
Assistant Vice Chancellor for Technology Transfer, 03/16/01
267. NorthShore University HealthSystem, Stephen Wachtel, Ph.D.,
Director, Research Development, 01/07/09
268. North Texas Health Science Center, University of, Research
and Biotechnology, Robert W. Gracy, Ph.D., Associate
VP, 04/26/04
269. Northeastern Ohio Universities, College of Medicine, Robert
S. Blacklow, MD, President and Dean, 07/16/95
270. Northeastern Ohio Universities College of Medicine, Robert
S. Blacklow, MD, President and Dean, 07/16/95
271. Northeastern University, William E. Kneeland, Jr.,
Controller, 05/19/05
272. Northern California Institute for Research and Education,
Jack Nagan, Chief Executive Officer, 09/10/99
273. Northern Illinois University, Jerrold H. Zar, Associate
Provost for Research, 04/03/95
274. Northern Kentucky University, William F. Thompson,
Director, Research, Grants and Contracts, 01/11/12
275. Northwestern University, Technology Transfer Program,
Indrani Mukharji, PhD, Director, 04/28/99
276. Notre Dame, University of, James L. Merz, Vice President
for Graduate Studies & Research, 05/14/97
277. Nova Southeastern University, Gary S. Margules, Sc.D., Vice
President, Office of Research and Technology Transfer,
03/31/10
278. Oakwood Healthcare, Inc., Gregory J. Bock, Designated
Institutional Official, 12/02/11
279. Odense University Hospital, Department of Hematopathology,
Michael B. Moller, Associate Professor, Director,
02/27/10
280. Ohio, Medical College of, R. Douglas Wilkerson, PhD,
Associate VP for Research, 07/12/95
281. Ohio State University, Technology Licensing, Robin L. Rasor
(Updated as of 10/15/02 Lisa Rooney, Acting Director),
Director, 12/20/99
282. Ohio University, Lisa Rooney, Director, Technology
Transfer, October 15, 2008
283. Oklahoma, The Board of Regents of the University of, W.
Arthur Porter, University Vice President for Technology
Development, 07/23/99
284. Oklahoma Medical Research Foundation, J. Donald Capra, MD,
President, 12/22/99
285. Oklahoma State University, Thomas C. Collins, PhD, Vice
President for Research, 01/25/96
286. Old Dominion University, Dr. Mohammad Karim, Vice President
Research, 03/21/05
287. Ontario Cancer Institute, Technology Transfer, Bob
McArthur, Director, 09/29/98
288. Oregon, University of, Technology Transfer, Don Gerhart,
Director, 04/02/98
289. Oregon Health Sciences University, Technology Management,
Sandra L. Shotwell, PhD, Director, 04/24/95
290. Oregon State University, Dr. George H. Keller, Vice Provost
for Research and International Programs, 07/03/95
291. Ottawa, University of, D. Joe Irvine, Director, Technology
Transfer & Business Enterprise, 08/22/06
292. Pennsylvania State University, Ronald J. Huss, Director,
Intellectual Property Office, 12/12/05
293. Pennsylvania, University of, Center for Technology
Transfer, Anthony Merritt, Executive Director, 05/02/95
294. Pioneer Valley Life Sciences Institute, Inc., Paul
Friedmann, PhD, Executive Director, 03/28/06
295. Pittsburgh, University of, Allen DiPalma, Director, Office
of Research, 7/1/08
296. Polytechnic University, Michael Klidas, Director of
Contracts and Grants, 06/22/06
297. Poudre Valley Health System, Stephanie Doughty, Vice
President/ Chief Financial Officer, 02/09/12
-
AUTM | Master UBMTA Agreement Signatories
http://www.autm.net/Technology_Transfer_Resources/8199.htm[2012/07/13
16:33:35]
298. Prairie View A&M University, William Trotty, Vice
President for Research and Development, 11/24/00
2